-
Je něco špatně v tomto záznamu ?
Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy
A. Babkova, L. Rob, M. Kubecova, M. Hruda, MJ. Halaska
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
Third Medical Faculty, Charles University in Prague
NLK
Directory of Open Access Journals
od 2022
PubMed Central
od 2022
ProQuest Central
od 2023-12-01
Health & Medicine (ProQuest)
od 2023-12-01
Wiley Free Content
od 1997
Wiley-Blackwell Open Access Titles
od 2022
PubMed
38226422
DOI
10.1111/aogs.14759
Knihovny.cz E-zdroje
- MeSH
- anemie * chemicky indukované diagnóza MeSH
- arteria cerebri media diagnostické zobrazování MeSH
- lidé MeSH
- nemoci plodu * chemicky indukované diagnostické zobrazování MeSH
- novorozenec MeSH
- protinádorové látky * MeSH
- rychlost toku krve MeSH
- těhotenství MeSH
- ultrasonografie prenatální MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Chemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. MATERIAL AND METHODS: The study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn. RESULTS: Five patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia. CONCLUSIONS: In four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014490
- 003
- CZ-PrNML
- 005
- 20240905133947.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/aogs.14759 $2 doi
- 035 __
- $a (PubMed)38226422
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Babkova, Anna $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0009000892686957
- 245 10
- $a Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy / $c A. Babkova, L. Rob, M. Kubecova, M. Hruda, MJ. Halaska
- 520 9_
- $a INTRODUCTION: Chemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. MATERIAL AND METHODS: The study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn. RESULTS: Five patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia. CONCLUSIONS: In four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a arteria cerebri media $x diagnostické zobrazování $7 D020768
- 650 _2
- $a rychlost toku krve $7 D001783
- 650 _2
- $a ultrasonografie prenatální $7 D016216
- 650 12
- $a anemie $x chemicky indukované $x diagnóza $7 D000740
- 650 12
- $a nemoci plodu $x chemicky indukované $x diagnostické zobrazování $7 D005315
- 650 12
- $a protinádorové látky $7 D000970
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rob, Lukas $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Kubecova, Martina $u Department of Oncology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Hruda, Martin $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Halaska, Michael J $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
- 773 0_
- $w MED00009026 $t Acta obstetricia et gynecologica Scandinavica $x 1600-0412 $g Roč. 103, č. 4 (2024), s. 660-668
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38226422 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133941 $b ABA008
- 999 __
- $a ok $b bmc $g 2143942 $s 1226356
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 103 $c 4 $d 660-668 $e 20240116 $i 1600-0412 $m Acta obstetricia et gynecologica Scandinavica $n Acta Obstet Gynecol Scand $x MED00009026
- GRA __
- $p Third Medical Faculty, Charles University in Prague
- LZP __
- $a Pubmed-20240725